Moderna’s mRNA-3927 Fast Track’d for rare metabolic disorder

The FDA has designated Moderna’s (NASDAQ:MRNA) mRNA-3927 for Fast Track review for the treatment of propionic acidemia, a rare inherited disorder in which the body cannot properly process certain parts of fats and proteins.

Clinical development is set to begin following the agency’s sign-off on the IND less than a month ago.

Fast Track status provides for more frequent interaction with the FDA review team and a rolling review of the marketing application.

https://seekingalpha.com/news/3508073-modernas-mrnaminus-3927-fast-trackd-rare-metabolic-disorder